Latest Breaking News On - தலைவலி கோளாறுகள் - Page 1 : vimarsana.com

ABBVie today announced that the New England Journal of Medicine  has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine. The study, which enrolled adult participants experiencing 4 to 14 migraine days per month, found that all active treatment arms of atogepant 10 mg, 30 mg, and 60 mg once-daily .

United statesCity ofUnited kingdomPeter goadsbyUniversity of california los angelesVirtual migraine trust international symposiumAmerican academy of neurology annual meetingDrug administrationInternational classification of headache disordersExchange commissionKing collegeMigraine research foundationNew england journalMichael goldMigraine specific qualityLife questionnaire